Barclays lowered the firm’s price target on Tenet Healthcare (THC) to $208 from $215 and keeps an Overweight rating on the shares post the Q2 report. The firm sees Affordable Care Act headwinds next year but says the concerns are overdone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $200 from $185 at Raymond James
- Tenet Healthcare price target raised to $188 from $180 at Guggenheim
- Tenet Healthcare price target raised to $238 from $230 at UBS
- Tenet Healthcare price target raised to $225 from $210 at Morgan Stanley
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare